TABLE 2

Screening outcome and celiac disease ascertainment in 2 birth cohorts of 12-y-olds.

1993 Cohortan (%)1997 Cohort n (%)
Positive serological markers
 tTG-IgA >4 U/mL167 (89)85 (82)
 tTG-IgA 2–4 U/mL and EMA-IgA >1:520 (11)19 (18)
 Total187104
 Girls10068
Small intestinal biopsy evaluation
 Marsh III139 (92)88 (99)
 Marsh II2 (1.3)0
 Marsh I and symptoms/signsb9 (6.0)1 (1.0)c
 Noninterpretable1 (0.7)d0
 Total number of cases15189
 Girls8057
HLA genotyping
 DQ2113 (75)71 (80)
 DQ2/DQ823 (15)8 (9.0)
 DQ815 (9.9)9 (10)
 Non-DQ2/DQ800
 Not available01 (1.0)e
  • a Data published previously.20,22

  • b Symptoms/signs include gastrointestinal complaints, tiredness, deviation in weight and/or height, heredity for celiac disease, anemia, and autoimmune disorders.

  • c Diagnosis based on tTG 3 U/mL, EMA 1/10, Marsh I enteropathy in combination with stomachache.

  • d Diagnosis based on tTG >100 U/mL because the biopsy was noninterpretable, but parents declined rebiopsy. After gluten-challenge: oral rhagades and additional tTG >100 U/mL.

  • e Diagnosis based on tTG >100 U/mL and Marsh III enteropathy.